Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market
1. Deloitte's report reveals royalty funding's growing significance in biopharma. 2. 87% of executives consider royalties for capital raising in next three years. 3. Royalties provide non-dilutive capital, attracting positive investment perceptions. 4. Royalty Pharma leads the market with a diversified portfolio of royalties. 5. The report highlights royalties' role in supporting innovation and financial success.